Cover Image
市場調查報告書

過敏性鼻炎:開發平台分析

Allergic Rhinitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232791
出版日期 內容資訊 英文 179 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎:開發平台分析 Allergic Rhinitis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 179 Pages
簡介

所謂過敏性鼻炎是免疫系統鼻子吸入的物質過度反應時所發生的過敏反應。

本報告提供過敏性鼻炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

過敏性鼻炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

過敏性鼻炎:企業開發中的治療藥

過敏性鼻炎:大學/機關研究中的治療藥

過敏性鼻炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

過敏性鼻炎:企業開發中的產品

過敏性鼻炎:大學/機關研究中的產品

過敏性鼻炎的治療藥的開發企業

  • 3M Drug Delivery Systems
  • Accolade Pharmaceuticals, LLC
  • Adamis Pharmaceuticals Corporation
  • AFFiRiS AG
  • ALK-Abello A/S
  • Ampio Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • ASIT biotech s.a.
  • Axikin Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Chrysalis BioTherapeutics, Inc.
  • ELORAC, Inc.
  • Faes Farma, SA
  • Fountain Biopharma Inc.
  • GenMont Biotech Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • HAL Allergy BV
  • Hanmi Pharmaceuticals, Co. Ltd.
  • 久光製藥
  • J Uriach Y Compania, S.A.
  • Johnson & Johnson
  • Laboratorios LETI S.L.
  • Ligand Pharmaceuticals, Inc.
  • Marinomed Biotechnologie GmbH
  • Merck & Co., Inc.
  • Panmira Pharmaceuticals, LLC.
  • Pfizer Inc.
  • Protectimmun GmbH
  • Regeneron Pharmaceuticals, Inc.
  • RODES Inc.
  • Roxall Medizin GmbH
  • Sanofi
  • 鹽野義製藥
  • Stallergenes SAS
  • 大鵬藥品工業
  • VentiRx Pharmaceuticals, Inc.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

過敏性鼻炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

過敏性鼻炎:最近的開發平台趨勢

過敏性鼻炎:暫停中的計劃

過敏性鼻炎:開發中止的產品

過敏性鼻炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8463IDB

Summary

Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
  • The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects
  • The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Rhinitis Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Rhinitis - Overview
    • Pipeline Products for Allergic Rhinitis - Comparative Analysis
  • Allergic Rhinitis - Therapeutics under Development by Companies
  • Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes
  • Allergic Rhinitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Allergic Rhinitis - Products under Development by Companies
  • Allergic Rhinitis - Products under Investigation by Universities/Institutes
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Accolade Pharmaceuticals, LLC
    • AFFiRiS AG
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • Ampio Pharmaceuticals, Inc.
    • Array BioPharma Inc.
    • ASIT biotech s.a.
    • Axikin Pharmaceuticals, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • Chrysalis BioTherapeutics, Inc.
    • ELORAC, Inc.
    • Faes Farma, S.A.
    • Fountain Biopharma Inc.
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • HAL Allergy BV
    • Hisamitsu Pharmaceutical Co., Inc.
    • Johnson & Johnson
    • Laboratorios LETI S.L.
    • Ligand Pharmaceuticals, Inc.
    • Marinomed Biotechnologie GmbH
    • Merck & Co., Inc.
    • Panmira Pharmaceuticals, LLC.
    • Paradigm Biopharmaceuticals Limited
    • Pfizer Inc.
    • Protectimmun GmbH
    • Roxall Medizin GmbH
    • Sanofi
    • Shionogi & Co., Ltd.
    • Stallergenes Greer plc
    • Sun Pharma Advanced Research Company Ltd.
    • Taiho Pharmaceutical Co., Ltd.
    • VentiRx Pharmaceuticals, Inc.
    • Xencor, Inc.
  • Allergic Rhinitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (azelastine hydrochloride + budesonide) - Drug Profile
    • (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
    • (levocabastine hydrochloride + mometasone furoate) - Drug Profile
    • 854-A - Drug Profile
    • Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
    • Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
    • AM-211 - Drug Profile
    • AM-461 - Drug Profile
    • Ampion - Drug Profile
    • AR-460770 - Drug Profile
    • Arabinogalactan - Drug Profile
    • asapiprant - Drug Profile
    • B-244 - Drug Profile
    • beta-escin - Drug Profile
    • bilastine - Drug Profile
    • budesonide - Drug Profile
    • CBP-174 - Drug Profile
    • cidoxepin hydrochloride - Drug Profile
    • clustoid wiesenlieschgras - Drug Profile
    • desloratadine - Drug Profile
    • emedastine difumarate - Drug Profile
    • esketamine hydrochloride - Drug Profile
    • FB-825 - Drug Profile
    • gp-ASIT - Drug Profile
    • GSK-2245035 - Drug Profile
    • GSP-301 - Drug Profile
    • Lactococcus lactis G121 - Drug Profile
    • motolimod - Drug Profile
    • nasapaque - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • PF-06444752 - Drug Profile
    • PF-06444753 - Drug Profile
    • Pollinex Quattro Tree - Drug Profile
    • rE58 - Drug Profile
    • Small Molecule for Allergic Rhinitis - Drug Profile
    • Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
    • Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile
    • Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
    • STAGR-120 - Drug Profile
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    • SUN-0597 - Drug Profile
    • TAS-205 - Drug Profile
    • Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
    • VTX-1463 - Drug Profile
    • XmAb-7195 - Drug Profile
    • Zafi-3 - Drug Profile
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Rhinitis, H2 2016
  • Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
  • Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2016
  • Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2016
  • Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Array BioPharma Inc., H2 2016
  • Allergic Rhinitis - Pipeline by ASIT biotech s.a., H2 2016
  • Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016
  • Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2016
  • Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2016
  • Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2016
  • Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2016
  • Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
  • Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
  • Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
  • Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2016
  • Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2016
  • Allergic Rhinitis - Pipeline by Sanofi, H2 2016
  • Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2016
  • Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Allergic Rhinitis - Dormant Projects, H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..2), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..3), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..4), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..5), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..6), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..7), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..8), H2 2016
  • Allergic Rhinitis - Dormant Projects (Contd..9), H2 2016
  • Allergic Rhinitis - Discontinued Products, H2 2016
  • Allergic Rhinitis - Discontinued Products (Contd..1), H2 2016
  • Allergic Rhinitis - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Allergic Rhinitis, H2 2016
  • Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top